November 2, 2017 10:28 AM EDT
News Briefing

Fo­cus­ing on next-gen can­cer drugs, GSK touts a ‘break­through’ at FDA; Ais­ling rais­es $280M fund

John Carroll

Editor & Founder

→ Any­one look­ing for fresh signs of Glax­o­SmithK­line’s plans to go much deep­er in­to on­col­o­gy should check out the phar­ma gi­ant’s no­tice that its mul­ti­ple …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times